Sg001 drug page Clinical trials

Trials with Sg001

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

3Trials
1Recruiting
1Countries
314Planned patients

Showing 1–3 of 3

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)
Recruiting Phase 2 44 patients NCT07183865

This is an open-label, single arm, phase 2 study. The study is to evaluate the activity of combination therapy of hypofractionated radiotherapy, Irinotecan Hydrochloride Liposome plus 5-FU and leucovorin (NALIRIF), Anti-PD1 and target ther…

China Mar 2025 – Mar 2030 Interventional
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
Not yet recruiting Phase 1 168 patients NCT06132217

This is an open-label Phase I/II trial of simmitinib plus SG001 in patients with advanced solid tumors. Phase I will determine and confirm the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for simmitinib in combination …

China Jan 2024 – Jan 2027 Interventional
Combined with: Simmitinib
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
Finished Phase 2 102 patients NCT06089330

This study is a phase Ⅱ, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with Irinotecan and SG001 in Patients with Metastatic Colorectal Cancer (mCRC).

Jan 2024 – Dec 2024 Interventional

Where the recruiting trials are